Mankind Pharma posts mixed performance in Q4; stock slips ~4%

22 May 2025 , 12:15 PM

Mankind Pharma Limited announced its results for the quarter ended March 2025 and posted a mixed set of numbers. Though the business reported a robust topline, it was offset by a slip in profit decline and margin contraction.

The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25. In the same quarter of previous year, the business logged a net profit of ₹471.20 Crore.

On the other hand, the company’s revenue from operations registered a growth of 27.10% to ₹3,079.40 Crore. The business said that revenue growth was primarily driven by strong traction in consumer healthcare, and consolidation of the acquired BSV business.

The company said that its EBITDA for the quarter under review witnessed a growth of 16.50% to ₹683.20 Crore. However, EBITDA margin witnessed a traction at 22.20% against 24.20% in the same quarter of previous year. 

To strengthen its specialty portfolio in super specialty therapies and gynaecology, Mankind has acquired Bharat Serums and Vaccines (BSV).

The company said that BSV integration is growing well, focusing on the improvement of R&D and expansion of key brands.

At around 12.05 PM, Mankind Pharma was trading 3.57% lower at ₹2,441 per piece, against the previous close of ₹2,531.40 on NSE. The counter touched an intraday high and low of ₹2,484.80, and ₹2,430, respectively.

For feedback and suggestions, write to us at [e-mail]